Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Following the recent declaration from the World Health Organization that the ongoing monkeypox outbreak is a Public Health Emergency of International Concern, the editorial teams at Nature Portfolio have curated a collection of relevant articles.
On the second anniversary of the identification of the causative agent of COVID-19, the npj Vaccines editorial team looks back on two years of uncertainty, but also astounding progress. Here we highlight a few stand out articles, from early calls for new vaccines, through to development of many prototypes and licensed vaccines, and finally looking at new variants, novel immunisations strategies, basic immunology, and inequalities in vaccine uptake.
Despite a marked decrease in cases and mortality, malaria is still estimated to result in over 405,000 deaths annually. Although a first vaccine against P. falciparum malaria is being piloted, much work is still needed to achieve the Global Technical Strategy for Malaria 2016–2030, from the World Health Assembly, to reduce global malaria incidence and mortality rates 90% by 2030.
The latest advances in malaria vaccine research are compiled in this collection.
Nature Partner Journals is an online-only, open access series of journals, collaborating with preeminent scientists and global partners to publish high-quality open access research across the applied and basic science disciplines, as well as multidisciplinary fields.
Our editors invite you to access articles from our range of journals publishing research in neuroscience. Browse all articles below.